In short. Most medical dermatology is chronic disease. Why relapse is expected rather than a failure, what monitoring systemic treatment requires, and what follow-up is actually for.
Key points
- Medicines taken for chronic skin disease are not like a short course of antibiotics.
- Several conventional immunosuppressants and biologic agents require blood tests before treatment begins and at intervals afterwards, and some require attention to blood pressure, infection risk or vaccination status.
- Those appointments are part of the treatment, not an optional extra, and missing them is the main avoidable risk.
Medical dermatology is largely a specialty of chronic disease. Eczema, psoriasis, chronic urticaria, recurrent skin infection, vitiligo, cutaneous lupus and blistering disease are all measured in years rather than weeks. That single fact shapes how they should be treated and what a patient should expect.
Why chronic skin disease behaves the way it does
These conditions share a pattern: they are controlled rather than cured, they relapse when treatment stops, and the factors that provoke a flare are often outside anyone’s control. A patient who expects a course of treatment to end the problem will read every relapse as a failure. A patient who understands the disease as something to be held in check will read the same relapse as a signal to treat early.
Relapse is expected, not a failure
It follows that the goal of treatment is control: the longest possible periods of quiet skin, achieved with the least treatment that works. Flares are then managed promptly rather than allowed to build, because inflammation that has been running for weeks settles more slowly than inflammation caught in the first days.
Systemic treatment carries monitoring
Medicines taken for chronic skin disease are not like a short course of antibiotics. Several conventional immunosuppressants and biologic agents require blood tests before treatment begins and at intervals afterwards, and some require attention to blood pressure, infection risk or vaccination status. Those appointments are part of the treatment, not an optional extra, and missing them is the main avoidable risk.
What long-term follow-up actually does
Follow-up is where the diagnosis is reconsidered if the response is atypical, where treatment is increased or reduced, where side effects and monitoring results are reviewed, and where the maintenance plan is rewritten for the next phase. It is also where treatment that has become unnecessary is stopped deliberately rather than abandoned accidentally.
Bring your actual tubes and boxes to the appointment, and be honest about what you have been able to use. A plan that is not being followed needs to change; a plan that is being followed and is not working needs the diagnosis looked at again.
Contact the clinic rather than waiting if
- The condition worsens significantly although treatment is being used as prescribed.
- New symptoms appear that were not part of the original problem, such as joint pain, fever or breathlessness.
- You cannot use the treatment as prescribed because of stinging, irritation or cost.
Frequently asked questions
Why do chronic skin diseases relapse when treatment stops?
Because they are controlled rather than cured, and the factors that provoke a flare are often outside anyone’s control. A patient who expects a course of treatment to end the problem reads every relapse as a failure; the same relapse is really a signal to treat early.
Why do systemic skin medicines need blood tests?
Several conventional immunosuppressants and biologic agents require blood tests before treatment begins and at intervals afterwards, and some require attention to blood pressure, infection risk or vaccination status. Those appointments are part of the treatment, and missing them is the main avoidable risk.
What is long-term follow-up actually for?
It is where the diagnosis is reconsidered if the response is atypical, where treatment is increased or reduced, where side effects and monitoring results are reviewed, and where treatment that has become unnecessary is stopped deliberately rather than abandoned accidentally.
Risks & Limitations
- Most chronic skin disease is managed rather than cured, and relapse is expected.
- Treatments typically need 8–12 weeks before response can be judged fairly.
- Topical treatment can cause irritation, dryness, peeling and photosensitivity.
- Systemic therapy may require blood monitoring and carries organ, metabolic and pregnancy risks.
- Isotretinoin in particular requires strict monitoring and pregnancy prevention.
- Pigment change is often slow and may be incomplete.
- No treatment works for everyone, and response cannot be predicted with certainty.
When to Seek Care
- A mole or lesion that changes in size, shape or colour, or starts to bleed, itch or crust.
- Fever with a widespread rash, blistering, or rash involving the eyes, mouth or genitals — seek emergency care.
- Rapidly spreading redness, swelling or pain in the skin.
- Facial swelling or difficulty breathing — possible severe reaction; seek emergency care immediately.
- New or worsening symptoms while taking a monitored medication.
References & Further Reading
- American Academy of Dermatology (AAD) — public and clinical guidance
- World Health Organization (WHO) — skin and infectious disease resources
- Chinese Medical Association, Dermatology Branch — clinical guidance
- Cochrane Library — systematic reviews in dermatology
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.